Cocaine and HIV-1 interplay in CNS: Cellular and molecular mechanisms

Current HIV Research

Volumn 10, Issue 5, 2012, Pages 425-428

  Buch, Shilpa ^a   Yao, Honghong ^a   Guo, Minglei ^b   Mori, Tomohisa ^c   Mathias Costa, Blaise ^a   Singh, Vijeta ^a   Seth, Pankaj ^d   Wang, John ^b   Su, Tsung Ping ^c  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d Molecular and Cellular Neuroscience   (United States)

Author keywords

AIDS; Cocaine; Glial cell; HIV; HIV 1 associated neurocognitive disorders; Neuron

Indexed keywords

CHEMOKINE; COCAINE; CYTOKINE; GLYCOPROTEIN GP 120;

BLOOD BRAIN BARRIER; CELL ACTIVITY; CELL MIGRATION; CELL TYPE; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; DISEASE COURSE; EPIDEMIOLOGICAL DATA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE; MACROGLIA; MICROGLIA; MOLECULAR MECHANICS; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; QUALITY OF LIFE; REVIEW; UPREGULATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; DISEASE PROGRESSION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INFLAMMATION MEDIATORS; MALE; MICROGLIA; UP-REGULATION; VIRUS REPLICATION;

EID: 84866317732     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212802138823     Document Type: Review

References (61)

1. Budka H. Neuropathology of human immunodeficiency virus infection. Brain Pathol 1991; 1(3): 163-175.
2. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43(11): 2245-2252.
3. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56(2): 257-260.
4. Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol 1992; 46: 655-693.
5. Gendelman HE, Lipton SA, Tardieu M, Bukrinsky MI, Nottet HS. The neuropathogenesis of HIV-1 infection. J Leukoc Biol 1994; 56(3): 389-398.
6. Lipton SA, Gendelman HE. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995; 332(14): 934-940.
7. Bell JE. The neuropathology of adult HIV infection. Rev Neurol (Paris) 1998; 154(12): 816-829.
8. Nath A. Pathobiology of human immunodeficiency virus dementia. Semin Neurol 1999; 19(2): 113-127.
9. Fiala M, Gan XH, Zhang L, et al. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? Adv Exp Med Biol 1998; 437: 199-205.
10. Larrat EP, Zierler S. Entangled epidemics: cocaine use and HIV disease. J Psychoactive Drugs 1993; 25(3): 207-221.
11. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective study of HIV disease progression in female and male drug users. AIDS 1999; 13(2): 257-262.
12. Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011; 44(1): 102-110.
13. Klein TW, Matsui K, Newton CA, Young J, Widen RE, Friedman H. Cocaine suppresses proliferation of phytohemagglutininactivated human peripheral blood T-cells. Int J Immunopharmacol 1993; 15(1): 77-86.
14. Mao JT, Huang M, Wang J, Sharma S, Tashkin DP, Dubinett SM. Cocaine down-regulates IL-2-induced peripheral blood lymphocyte IL-8 and IFN-gamma production. Cell Immunol 1996; 172(2): 217-223.
15. Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 1997; 156(5): 1606-1613.
16. Eisenstein TK, Hilburger ME. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol 1998; 83(1-2): 36-44.
17. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16(2): 209-219.
18. Bagasra O, Pomerantz RJ. Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. J Infect Dis 1993; 168(5): 1157-1164.
19. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990; 4(9): 869-873.
20. Nair MPN, Mahajan S, Hou J, Sweet AM, Schwartz SA. The stress hormone, cortisol, synergizes with HIV-1 gp-120 to induce apoptosis of normal human peripheral blood mononuclear cells. Cell MolBiol(Noisy-le-grand) 2000; 46(7): 1227-1238.
21. Roth MD, Tashkin DP, Choi R, Jamieson BD, Zack JA, Baldwin GC. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis 2002; 185(5): 701-705.
22. Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 2003; 309(1): 99-107.
23. Anthony JC, Vlahov D, Nelson KE, Cohn S, Astemborski J, Solomon L. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol 1991; 134(10): 1175-1189.
24. Baldwin GC, Roth MD, Tashkin DP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 1998; 83(1-2): 133-138.
25. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261(4): 561-565.
26. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000; 14(6): 717-726.
27. Chiasson MA, Stoneburner RL, Hildebrandt DS, Ewing WE, Telzak EE, Jaffe HW. Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS 1991; 5(9): 1121-1126.
28. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64(6): 529-536.
29. Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE. Upregulation of microglia in drug users with and without presymptomatic HIV infection. Neuropathol Appl Neurobiol 1999; 25(5): 369-379.
30. Anthony IC, Bell JE. The Neuropathology of HIV/AIDS. Int Rev Psychiatry 2008; 20(1): 15-24.
31. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 2008; 20(1): 25-31.
32. Yang Y, Yao H, Lu Y, Wang C, Buch S. Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120. PLoS One 2010; 5(10): e13427.
33. Khurdayan VK, Buch S, El-Hage N, et al. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci 2004; 19(12): 3171-3182.
34. El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, Hauser KF. Synergistic increases in intracellular Ca2+, and the release of MCP- 1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 2005; 50(2): 91-106.
35. Yao H, Yang Y, Kim KJ, et al. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 2010; 115(23): 4951-4962.
36. Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Peterson PK. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int Immunopharmacol 2006; 6(6): 1029-1033.
37. New DR, Ma M, Epstein LG, Nath A, Gelbard HA. Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 1997; 3(2): 168-173.
38. Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res 2000; 879(1-2): 42-49.
39. Gurwell JA, Nath A, Sun Q, et al. Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 2001; 102(3): 555-563.
40. Savio T, Levi G. Neurotoxicity of HIV coat protein gp120, NMDA receptors, and protein kinase C: a study with rat cerebellar granule cell cultures. J Neurosci Res 1993; 34(3): 265-272.
41. Lipton SA, Sucher NJ, Kaiser PK, Dreyer EB. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron 1991; 7(1): 111-118.
42. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410(6831): 988-994.
43. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999; 96(14): 8212-8216.
44. Turchan J, Anderson C, Hauser KF, et al. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2001; 2(1): 3.
45. Nath A, Hauser KF, Wojna V, et al. Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 2002; 31 Suppl 2: S62-S69.
46. Maragos WF, Young KL, Turchan JT, et al. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 2002; 83(4): 955-963.
47. Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000; 14(3): 222-227.
48. Koutsilieri E, Gotz ME, Sopper S, et al. Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro. J Neurovirol 1997; 3(5): 342-349.
49. Yao H, Allen JE, Zhu X, Callen S, Buch S. Cocaine and human immunodeficiency virus type 1 gp120 mediate neurotoxicity through overlapping signaling pathways. J Neurovirol 2009; 15(2): 164-175.
50. Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 2006; 27(2): 217-228.
51. Bagetta G, Piccirilli S, Del Duca C, et al. Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurosci Lett 2004; 356(3): 183-186.
52. Banks WA, Farr SA, Morley JE. Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse. J Gerontol A Biol Sci Med Sci 2000; 55(12): B601-B606.
53. Persidsky Y, Stins M, Way D, et al. A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 1997; 158(7): 3499-510.
54. Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 1996; 156(3): 1284-1295.
55. Fiala M, Gan XH, Zhang L, et al. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? Adv Exp Med Biol 1998; 437: 199-205.
56. Gan X, Zhang L, Berger O, et al. Cocaine enhances brain endothelial adhesion molecules and leukocyte migration. Clin Immunol 1999; 91(1): 68-76.
57. Lee YW, Hennig B, Fiala M, Kim KS, Toborek M. Cocaine activates redox-regulated transcription factors and induces TNFalpha expression in human brain endothelial cells. Brain Res 2001; 920(1-2): 125-133.
58. Chang SL, Bersig J, Felix B, Fiala M, House SD. Chronic cocaine alters hemodynamics and leukocyte-endothelial interactions in rat mesenteric venules. Life Sci 2000; 66(24): 2357-2369.
59. Gan X, Zhang L, Newton T, et al. Cocaine infusion increases interferon-gamma and decreases interleukin-10 in cocainedependent subjects. Clin Immunol Immunopathol 1998; 89(2): 181-190.
60. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14(7): 731-737.
61. Yao H, Duan M, Buch S. Cocaine-mediated induction of plateletderived growth factor: implication for increased vascular permeability. Blood 2011; 117(8): 2538-2547.